Boehringer's survodutide beat placebo on weight loss in Phase 3 trial, NEJM reports

Adults with obesity and without diabetes lost significantly more weight on once-weekly survodutide than on placebo over 76 weeks, according to a Phase 3 trial published June 7 in the New England Journal of Medicine ^[1]. Survodutide is an investigational dual glucagon receptor and GLP-1 receptor agonist developed by Boehringer Ingelheim and is not approved for any use ^[1].

The trial, called SYNCHRONIZE-1, randomly assigned 725 adults in a 1:1:1 ratio to one of two survodutide doses or placebo, all given as subcutaneous injections once a week along with counseling for lifestyle modification ^[1]. Participants had a body-mass index of 30 or higher, or 27 or higher with at least one obesity-related complication, but not diabetes ^[1]. Their mean age was 47.1 years, and 294 of them (40.6%) were men. At enrollment, mean BMI was 37.9 and mean body weight was 108.8 kg ^[1].

At week 76, mean body weight fell 12.2% (95% confidence interval, −13.6 to −10.8) in the 3.6 mg group, 13.0% (95% CI, −14.4 to −11.6) in the 6.0 mg group and 5.4% (95% CI, −6.9 to −4.0) in the placebo group ^[1]. The share of participants who lost at least 5% of their body weight was 72.6% at 3.6 mg, 71.9% at 6.0 mg and 46.3% on placebo, with P<0.001 for both comparisons against placebo ^[1].

The main analysis used a treatment-regimen estimand, which the authors describe as incorporating the effects of early discontinuation of survodutide or placebo, the use of obesity medications prohibited by the protocol, and a prolonged dose-escalation period ^[1]. The published figures therefore reflect what happened to everyone assigned to each group, not only those who stayed on treatment.

Gastrointestinal symptoms were the most common side effects, reported by 80.9% of the 3.6 mg group, 89.7% of the 6.0 mg group and 47.9% of the placebo group. They were typically mild to moderate ^[1]. No deaths were reported ^[1]. The published summary does not report rates of serious adverse events or how many participants stopped treatment because of side effects.

The trial was funded by Boehringer Ingelheim and registered as NCT06066515 ^[1].

Why it matters for patients

Survodutide cannot be prescribed today, and no US approval is in place ^[1]. People weighing semaglutide (sold as Ozempic, Wegovy and Rybelsus) or tirzepatide (Mounjaro and Zepbound) have no option to choose survodutide, and it is not yet known whether that will change.

The results also show how much weight the placebo group lost: 5.4% on average over 76 weeks with lifestyle counseling alone ^[1]. That is the comparison any new obesity drug is measured against in this trial.

The side-effect pattern is similar in shape to other GLP-1-based treatments, with gastrointestinal symptoms dominating and occurring more often at the higher dose — 89.7% at 6.0 mg versus 80.9% at 3.6 mg ^[1]. The published summary does not report how many people stopped treatment because of those symptoms, which is often a key number for patients who have struggled to tolerate this class of drugs.

Cost, insurance coverage and how survodutide might compare head-to-head with approved drugs have not been reported ^[1].

What happens next

NEJM published the article online on June 7, 2026, and updated it on July 23, 2026. It appears in the August 20, 2026 print issue, volume 395, number 8, pages 776–787 ^[1].

Whether Boehringer Ingelheim has filed for US regulatory review, when the drug might reach the market, and whether results from additional trials are coming have not been reported ^[1].